On 3 June 2008, orphan designation (EU/3/08/546) was granted by the European Commission to Talecris Biotherapeutics GmbH, Germany, for alpha-1 proteinase inhibitor (for inhalation use) for the treatment of congenital alpha-1 antitrypsin deficiency.
In February 2012, Talecris Biotherapeutics GmbH changed name to Grifols Deutschland GmbH.
Treatment of congenital alpha-1 antitrypsin deficiency
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
EU/3/08/546: Public summary of positive opinion for orphan designation of alpha-1 proteinase inhibitor (for inhalation use) for the treatment of congenital alpha-1 antitrypsin deficiency (PDF/127.79 KB)
First published: 18/08/2008
Last updated: 17/10/2013
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: